“…Genetic studies of CTG clade species expanded in the 2000s and focused on the development of molecular tools, as well as transformation procedures, due to the biotechnological potential of several Candida yeasts ( C. guilliermondii , C. famata , C. tropicalis , and C. rugosa ) as well as clinical incidence ( C. dubliniensis and C. parapsilosis ) [5], [9]. Specifically, drug-resistant markers and reporter genes (encoding fluorescent protein variants, luciferase, or beta-galactosidase) were adapted by changing CTG codons to allow their functionality in this particular clade [5] (Table 1). …”